COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT05109611

Keith Moore

Not reported

2021-11-05

Not recruiting

RCT

Randomized

Parallel

Blind label

multi-center

Prevention

inclusion criteria each participant must meet the following criteria to be enrolled in this study. at least aged 18 years old at the time of consent. if female, be surgically sterile or post-menopausal (no menses for at least 12 months), or if of childbearing potential, must be using an acceptable method of contraception such as a combination estrogen/progestin hormonal contraceptive (oral or injected) for at least 1 month prior to day 1, or such items as an iud, intrauterine system (ius), transdermal hormonal implant, vaginal hormonal ring, or 2 forms of the following: diaphragm, cervical cap, patch, condom, spermicide, or sponge. total abstinence is permitted. if local regulations deviate from the previously listed contraception methods to prevent pregnancy, local requirements will apply. in addition, females of childbearing potential must agree to continue to use their method of birth control for the duration of the study and 12 weeks following discharge from the study. if male, be surgically sterile, or agree to use appropriate contraception (latex condom with spermicide) when engaging in sexual activity and agree to not donate sperm for the duration of the study and 12 weeks following discharge from the study. be in good health (ie, no acute illnesses or hospitalizations within 30 days of the study start, no planned procedures during study participation, and no newly diagnosed chronic illnesses that are not deemed stable by the participant's primary care physician), in the opinion of the investigator, based on medical history (ie, absence of any clinically relevant abnormality) during screening. be able to understand and provide written, informed consent. access to a telephone, the internet, a device that reliability connects to the internet, and able to dial into telehealth checkups and study-related assessments. if access to the internet precludes involvement, then paper diaries may be completed and promptly entered into the data capture system at the study centers as part of the regular follow-up visits. must be able to receive study product shipments directly to their home (ie, no post office boxes), unless in a region (eu) or other location where the participant must receive the study product directly from the sites' staff/physician.

participants who meet any of the following criteria will be excluded from the study. participants with acute illnesses or hospitalizations within 30 days of the study start, and/or planned procedures during study participation, and/or newly diagnosed chronic illnesses that are not deemed stable by the participant's primary care physician), based on investigator assessment of medical history during screening. participants with any respiratory infection, flu-like symptoms, or unexplained fever or chills during the week prior to screening (see section 6.6.2). participants with any prior history of sars-cov-2 infection. participants who use intranasally dosed drugs, prescriptions or over-the-counter medications such as fluticasone within the last 7 days. participants who underwent a previous tracheostomy. participants who are receiving any form of oxygen therapy. females who are breastfeeding, pregnant, or attempting to become pregnant. participants who have any other condition that, in the opinion of the investigator, would interfere with a participant's ability to adhere to the protocol (eg, participants whom are mentally or neurologically disabled and whom are considered not fit to their participation in the study), interfere with assessment of the investigational product, or compromise the safety of the participant or the quality of the data.

2

Sanotize Research and Development corp.

18

100

Canada;Sri Lanka

Healthy volunteers

N/A

1389

To assess the efficacy of NONS in the reduction of risk of COVID-19 infection.

None

Phase 3

[{"arm_notes": "", "treatment_id": 1890, "treatment_name": "Nitric oxide nasal spray", "treatment_type": "Nasal spray", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]